Main Article Content


Diabetes Mellitus is a serious problem universally, by and large in both developing as well as underdeveloped nations. Conversely, a synthetic drug management of diabetes mellitus creates an unexpected adverse effect towards all organs and it is not safeguarding too. However, numerous enzymes, which is a real concern and may be accountable for diabetes mellitus and its associated complications, which would certainly afford a plenty of scope and platform to explore out the main target enzyme. These enzymes are to be targeted in treating diabetes mellitus may have a proven advantage in reducing the diabetes mellitus consequences. There are several evidences indicated Protein Tyrosine Phosphatase and variety of isomers are responsible diabetes mellitus, however Protein Tyrosine Phosphatase and its isomers are hardly targeted, due to inappropriate clinically validation lapse. Researchers are clinically validating the indeterminate Protein Tyrosine Phosphatase to establish an efficient method for variability of Protein Tyrosine Phosphatase enzyme levels of various clinical conditions of diabetes mellitus and its associated diseases.


Diabetes Mellitus Protein Tyrosine Phosphatase Synthetic drugs clinically validation Researcher

Article Details

How to Cite
G. Nagaraja Perumal, & S.Mohan. (2021). Prediction of target enzyme for diabetes mellitus by isolated blood samples. International Journal of Research in Pharmacology & Pharmacotherapeutics, 5(3), 209-214. Retrieved from


  1. [1]. Mohan S and Nandha kumar L. Role of various flavonoids: Hypotheses on novel approach to treat diabetes. J Med Hypotheses Ideas.6 2014, 1-6.
  2. [2]. Ozara Tabetabaei Malazy, Bagher Larijani and et al, A Novel Management of Diabetes by means of Strong Antoxidants’ Combination. J Med Hypotheses Ideas. 7, 2013, 25-30.
  3. [3]. IDF diabetes atlas. International Diabetes federation.15, 2011, 1-120.
  4. [4]. Abdollahi M, Ranjbar A and Shadnia. Pesticides and oxidative stress: A review. Med Sci Monit.10, 2004, 141–147.
  5. [5]. Rahimi R, Nikfar S and Larijani B. A review on the role of antioxidants in the management of diabetes and its complications (Carolina USA). Biomed Pharmacother. 59, 2005, 365–73.
  6. [6]. Guyton A C and Hall J E, Text Book of Medical Physiology. New York, McGraw Hill; United States of America. 1996, 855-863.
  7. [7]. Stphen G N Davis and Daryl K Granner, the Pharmacological Basis of Therapeutics. Edn 5 Vol 1 Pharmacology of the Endocrine Pharmacology, McGraw Hill Professional, New York, USA, 2010, pp.1679-1715.
  8. [8]. Global health risks, Mortality and burden of disease attributable to selected major risks. World Health Organization, 2009, 1-127.
  9. [9]. Danaei G, Finucane MM, Lu Y, Singh GM, National, regional and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7millionparticipants. Lancet. 378 2011. 31–40.
  10. [10]. Mathers CD and Loncar D, 2006. Projections of global mortality and burden of disease from, to 2030. PLoSMed, 3, 2002, 442.
  11. [11]. Harris M Alberti K,Zimmet P, Defronzo R. And Zimmet P. International Text Book of Diabetes Mellitus. Edn 7 Vol1 Chichester, John Wiley and Sons publication United Kingdom, 1997, 9–23.
  12. [12]. Ta.batabaei-Malazy O, Larijani B and Abdollahi M. A systematic review of in vitro Studies conducted on effect of herbal products on secretion of insulin from Langerhans Islets. J Pharm Sci. 15, 2012,447–466.
  13. [13]. Mohammadi M, Atashpour S and Pourkhalili. Comparative improvement in function of isolated rat Langerhans islets by various phosphodiesterase 3, 4 and 5 inhibitors. Asian J Anim Vet Adv.12, 2011, 233–40.
  14. [14]. Mehri A, Hasani-Ranjbar S and Larijani B, A systematic review of efficacy and safety of Urtica dioica in the treatment of diabetes. Int J Pharmacol. 7, 2011, 161–70.
  15. [15]. Mohseni-Salehi-Monfared SS and Larijani B. Islet transplantation and antioxidant management: a comprehensive review.World J Gastroenterol. 15, 2009, 1153–61.
  16. [16]. Matthias M. Ledig, Fawaz Haj and John L. Bixby. The Receptor Tyrosine Phosphatase Crypα Promotes Intraretinal Axon Growth. J.Cell Biol. 18, 1999, 375– 388.
  17. [17]. Angiola Petrone and Jan Sap. Emerging issues in receptor protein tyrosine phosphatase function: lifting for simply shifting?. J Cell Scie. 113, 2000, 2345- 2354.
  18. [18]. Jeffrey D Bjorge, Andrew Jakymiw and Donald J Fujita. Selected glimpses into the activation and function of Src kinase. Oncogene. 21, 2000, 5620-5635.
  19. [19]. Sundaram Nambirajan, Vegesna Radha and Shubhangi Kamatkar. PTP-S2, a nuclear tyrosine phosphatase, is phosphorylated and excludedfrom condensed chromosomes during mitosis. J Biosci.25, 2000, 33-40.
  20. [20]. Barbara Tremper-Well, Ross J. Resnick1in Zheng and Leslie J. Holsinger2.Extracellular domain dependence of PTP A transforming activity Shalloway. Genes to Cells.15, 2010, 711–724.
  21. [21]. Tzu-Ching Meng and Toshiyuki Fukada Reversible Oxidation and Inactivation of Protein Tyrosine Phosphatases InVivo. Mol Cell.9, 2002, 387–399.
  22. [22]. Kjeld Norris, Fanny Norris, Dwight H Kono and Henrik Vestergaard. Expression of Protein-tyrosine phosphatases in the major insulin target tissues. FEBS Letters, 415 1997, 243-24.
  23. [23]. John V. Frangioni, Pamela H. Beahm and Victor Shifrin. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence Cell. 68, 1992, 545-560
  24. [24]. Zhang Z.Y and Dixon J.E. Active site labeling of the Yersinia Protein Tyrosine Phosphatase: the determination of the pKa of the active site cysteine and the function of The conserved histidine 402 . Biochem.32, 1993, 9340–9345.
  25. [25]. Wiljan J.A.J. Hendriks and Rafael Pulido. Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities. Biochimica et Biophysica Acta.10, 2013, 1673-1696.
  26. [26]. Thareja S, Aggarwal S and Bhardwaj; Protein tyrosine phosphatase 1B inhibitors: a molecular level legitimate approach for the management of diabetes mellitus. Med Res Rev. 32, 2012, 459-517.
  27. [27]. Rong-jun He, Zhi-hong Yu and Ruo-yu Zhang. Protein tyrosine Phosphatases as potential therapeutic targets. Acta Pharmacol Sin,35, 2014,1227– 1246.
  28. [28]. Yang Y, Gil MC and Choi EY. Molecular cloning and chromosomal localization of a human gene homologous to the murine R-PTP-kappa, a receptor-type protein tyrosine phosphatase. Gene, 20, 1999, 77-82.
  29. [29]. Faiyaz Ahmad, John L. Azevedo, Jr and Ronald Cortright. Goldstein Alterations in Skeletal Muscle Protein–Tyrosine Phosphatase Activity and Expression in Insulin-resistant Human Obesity and Diabetes. J. Clin Invest.100, 1997, 449–458.
  30. [30]. Jeffrey D. Bjorge, Andrew Pang and Donald J. Fujita, Identification of Protein-tyrosine Phosphatase 1B as the Major Tyrosine Phosphatase Activity Capable of Dephosphorylating and Activating c-Src in Several Human Breast Cancer Cell Lines. The J Biol Chem.275, 2000, 41439-41446.
  31. [31]. Angeliki Malliri and John G Collard, Role of Rho-family proteins in cell adhesion and Cancer. Curr Opin Cell Biol.15, 2003, 583-589
  32. [32]. Sheila M. Thomas and Joan S. Brugge Cellular Functions Regulated By Src Family Kinases. Annu Rev Biol. 13, 1997, 513-609.
  33. [33]. Yoshimasa Nakamura, Nikolay Patrushev and Hyoe Inomata. Role of Protein Tyrosine Phosphatase 1B in Vascular Endothelial Growth Factor Signaling and Cell–Cell Adhesions in Endothelial Cells. Cir Res.102, 2008, 1182-1191.
  34. [34]. Yang Y, Gil MC and Choi EY. Molecular cloning and Chromosomal localization of a human gene homologous to the murine R-PTP-kappa, a receptor-type protein tyrosine phosphatase. Gene.186, 1997, 77-82.
  35. [35]. Jamieson CR, van der Burgt I and Brady AF. Mapping a gene for Noonan syndrome to the long arm of chromosome 12. Nat. Genet. 8, 1994, 357-360.
  36. [36]. Freeman RM Jr, Plutzky Jand Neel BG.Freeman. Identification of a human src homology 2-containing protein-tyrosine-phosphatase: A putative homolog of Drosophila. Natl. Acad. Sci. 23, 1992, 11239-11243.
  37. [37]. Roach T, Slater S and Koval M, CD45 regulates src family member kinase activity associated with macrophage integrin- mediated adhesion. Curr Biol. 7, 1997, 408–417.
  38. [38]. Eok-Soo Oh, Haihua Gu, Tracy M and et al, Regulation of Early Events in Integrin Signaling by Protein Tyrosine PhosphataseSHP-2. Mol Cell Biol. 19, 1999, 3205– 3215.
  39. [39]. Global status report on noncommunicable diseases. World Health Organization. 2010, 101- 110.
  40. [40]. Quang Nguyen, Loida Nguyen and James V Felcetta, Evaluation and Management of Diabetes Mellitus. America.Heal & Drug Benefits. 1, 2008, 1-8.
  41. [41]. Pranav K. Prabhakar and Mukesh Doble. A Target Based Therapeutic Approach Towards Diabetes Mellitus Using Medicinal Plants. Current Diabetes Review. 4, 2008, 291-308.
  42. [42]. Abiru N, Takino H and Yano M. Clinical Evaluation of Non-Insulin Dependent Diabetes Mellitus Patients with Auto Antibodies to Glutamic Acid Decarboxylase. J.Autoimmun. 5, 1996, 683-688.
  43. [43]. James R. Sover and murray Epstein. Diabetes Mellitus Associated Hypertension, Vascular Disease and Nephropathy Cells. Hypertension. 26, 1995, 869-879.
  44. [44]. Srinivasan R and Ramya G, Adverse Drug Reaction- Causality Assessment (Publishers, In- IJPCR, 35, PrintersNagarII, SitabariTonkRoad, Jaipur, Rajasthan, India). Int. J. Pharma.Clinical.13, 2011, 2231-34.
  45. [45]. Dabhade suhas and Bhosle Dr.Deepak, Review on Pharmacovigilance study of Telmisartan in Hypertension Patients. Asian.J.Pharma.Clinic.Res.6, 2013, 10974- 75.
  46. [46]. James M:Mc Kenney, Judith M. Slining and Richard Henderson. The Effect of Clinical Pharmacy Services on Patients with Essential Hypertension. Cir. 48, 1973, 1104-1111.
  47. [47]. Mandavi, Sanjay D Cruz, Atul Sachdev and Pramil Tiwari. Adverse drug reactions & their risk factors among Indian ambulatory elderly patients. Ind J Med Res.136, 2012, 404- 410.
  48. [48]. Himanshu Sharma, Mohammed Aqil, Faisal Imam. A Pharmacovigilance study in the department of medicine of a university teaching hospital. Pharm Pract.5, 2012, 46-49.
  49. [49]. Law MR, Wald NJ and Morris JK. Value of Low dose Combination treatment with blood pressure lowering drugs. Anal.BMJ.326, 2003, 1427-31.
  50. [50]. Adigun AQ, Ishola DA, Akintomide AO. Shifting trends in the Pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmacoeconomics of old and newer antihypertensive drugs. J. Hum. Hyp.17, 2003, 277-285.
  51. [51]. G.Liamis, H. Milionis and M.Elisaf. Blood pressure drug therapy and electrolyte Disturbances. Int J.Clin Practice.1 2008, 1572-1579.
  52. [52]. Nilima A.Kshirsagar and Sunil Karande. Adverse Drug Reaction Monitoring in Pediatric Practice. J. of Ind. Pediatric.33, 1996, 993-996.
  53. [53]. Hasford J, Mimran A and Simons WR. A Population-based European cohort study of Persistence in newly diagnosed hypertensive patients. J. Hum. Hyp.16, 2002, 569-575.
  54. [54]. Gene Nomenclature Committee reported on Protein tyrosine phosphataseses, including dual specificity of phosphatases; 2014; http/
  55. [55]. Wright JE, Wright AM. Bol Soc Argent Bot. 40, 2005, 1–2.
  56. [56]. Canas AI, Camarero S. Laccases and their natural mediators:biotechnological tools for sustainable eco-friendly processes. Biotechnol Adv. 28, 2010,694–705.
  57. [57]. Lundell TK, Mäkelä MR, Hildén K. Lignin-modifying enzymesin filamentous basidiomycetes ecological, functional andphylogenetic review. J Basic Microbiol.5, 2010, 5–20.
  58. [58]. Welti S, Moreau PA, and Favel A, Molecular phylogeny ofTrametes and related genera, and description of a new genus Leiotrametes. Fungal Div.55, 2012, 47–64.
  59. [59]. Baldrian P, Gabriel J. Lignocellulose degradation by Pleurotusostreatus in the presence of cadmium. J FEMS Microbiol Lett. 220, 2003, 235–240.
  60. [60]. Preussler CA, Shimizu E, Villalba LL and Zapata PD. Review of Trametes villosa.Rev Ciencia Tecnol. 12, 2009, 9–16.